ID25478A - Agonis 5-ht1f - Google Patents

Agonis 5-ht1f

Info

Publication number
ID25478A
ID25478A IDW20000837A ID20000837A ID25478A ID 25478 A ID25478 A ID 25478A ID W20000837 A IDW20000837 A ID W20000837A ID 20000837 A ID20000837 A ID 20000837A ID 25478 A ID25478 A ID 25478A
Authority
ID
Indonesia
Prior art keywords
ht1f
agonic
compounds
employing
chem
Prior art date
Application number
IDW20000837A
Other languages
English (en)
Indonesian (id)
Inventor
Sandra Ann Filla
Brian Michael Mathes
John Mehnert Schaus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ID25478A publication Critical patent/ID25478A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
IDW20000837A 1997-11-14 1998-11-13 Agonis 5-ht1f ID25478A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/970,637 US5905084A (en) 1997-11-14 1997-11-14 5-HTIF -agonists effective in treating migraine

Publications (1)

Publication Number Publication Date
ID25478A true ID25478A (id) 2000-10-05

Family

ID=25517243

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000837A ID25478A (id) 1997-11-14 1998-11-13 Agonis 5-ht1f

Country Status (22)

Country Link
US (1) US5905084A (fr)
EP (1) EP0916670B1 (fr)
JP (1) JP2001522887A (fr)
KR (1) KR20010032085A (fr)
CN (1) CN1284874A (fr)
AT (1) ATE240326T1 (fr)
AU (1) AU1407299A (fr)
BR (1) BR9814188A (fr)
CA (1) CA2310248A1 (fr)
DE (1) DE69814563T2 (fr)
DK (1) DK0916670T3 (fr)
EA (1) EA200000522A1 (fr)
ES (1) ES2198657T3 (fr)
HR (1) HRP20000297A2 (fr)
HU (1) HUP0004317A3 (fr)
ID (1) ID25478A (fr)
IL (1) IL135634A0 (fr)
NO (1) NO20002408L (fr)
PL (1) PL340459A1 (fr)
PT (1) PT916670E (fr)
TR (1) TR200001724T2 (fr)
WO (1) WO1999025348A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382247C (fr) * 1999-08-12 2010-09-28 Nps Allelix Corp. Azaindoles possedant une affinite pour le recepteur de serotonine
AU1570701A (en) * 1999-10-19 2001-04-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the 5-hydroxytryptamine (serotonin) receptor 1e gene
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2004094380A1 (fr) 2003-04-18 2004-11-04 Eli Lilly And Company Composes (piperidinyloxy)phenyle, (piperidinyloxy)pyridinyle, (piperidinylsulfanyl)phenyle et (piperidinylsulfanyl)pyridinyle utilises comme agonistes des recepteurs 5-ht1f
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
JP2007516266A (ja) 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー 5−ht1fアゴニストとしての置換(4−アミノシクロヘキセン−1−イル)フェニルおよび(4−アミノシクロヘキセン−1−イル)ピリジニル化合物
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
WO2011123654A1 (fr) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions et méthodes de synthèse d'agonistes des récepteurs 5-ht1f dérivés de la pyridinoylpipéridine
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19185A (es) * 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
MX9706969A (es) * 1995-03-20 1997-11-29 Lilly Co Eli 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists

Also Published As

Publication number Publication date
EP0916670B1 (fr) 2003-05-14
PL340459A1 (en) 2001-02-12
NO20002408D0 (no) 2000-05-09
WO1999025348A1 (fr) 1999-05-27
HRP20000297A2 (en) 2000-12-31
AU1407299A (en) 1999-06-07
BR9814188A (pt) 2000-10-03
DE69814563D1 (de) 2003-06-18
ES2198657T3 (es) 2004-02-01
PT916670E (pt) 2003-09-30
DK0916670T3 (da) 2003-09-15
DE69814563T2 (de) 2004-04-08
TR200001724T2 (tr) 2000-11-21
EP0916670A3 (fr) 2001-05-23
HUP0004317A3 (en) 2002-03-28
KR20010032085A (ko) 2001-04-16
CA2310248A1 (fr) 1999-05-27
CN1284874A (zh) 2001-02-21
JP2001522887A (ja) 2001-11-20
IL135634A0 (en) 2001-05-20
EA200000522A1 (ru) 2000-10-30
NO20002408L (no) 2000-07-12
ATE240326T1 (de) 2003-05-15
US5905084A (en) 1999-05-18
EP0916670A2 (fr) 1999-05-19
HUP0004317A2 (hu) 2001-10-28

Similar Documents

Publication Publication Date Title
ATE253063T1 (de) 5-ht1f-agonisten
DK1200418T3 (da) Nematodicide trifluorbutener
BR9914044A (pt) ésteres tetrahidropirido
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
DE60324544D1 (de) Muskarin antagonisten
PT882726E (pt) Carbazol-carboxamidas como agonistas 5-ht1f
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
TR200101978T2 (tr) 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri.
SE9802937D0 (sv) Novel compounds
SE0003476D0 (sv) Compounds
ID25478A (id) Agonis 5-ht1f
BR9902084A (pt) Heterociclos.
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
PE61999A1 (es) Compuestos de tetrahidropiridina